Taysha gene therapies reports fourth quarter and full year 2022 financial results and provides corporate update

Initiated screening of first potential subject in phase 1/2 reveal trial in rett syndrome; dosing of first adult patient with tsha-102 expected in h1 2023; submitted protocol amendment to allow for younger patients; initial available phase 1/2 clinical data, primarily on safety, expected in h1 2023
TSHA Ratings Summary
TSHA Quant Ranking